Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-Current Assets (2016 - 2025)

Cytosorbents' Non-Current Assets history spans 15 years, with the latest figure at $23.5 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $23.5 million for Q4 2025, down 8.62% from a year ago — trailing twelve months through Dec 2025 was $98.4 million (down 14.86% YoY), and the annual figure for FY2025 was $23.5 million, down 8.62%.
  • Non-Current Assets for Q4 2025 was $23.5 million at Cytosorbents, down from $24.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $31.5 million in Q2 2024 to a low of $7.8 million in Q1 2021.
  • The 5-year median for Non-Current Assets is $27.2 million (2022), against an average of $26.0 million.
  • The sharpest move saw Non-Current Assets surged 249.53% in 2022, then fell 21.69% in 2025.
  • Year by year, Non-Current Assets stood at $25.2 million in 2021, then increased by 16.86% to $29.5 million in 2022, then dropped by 6.49% to $27.6 million in 2023, then dropped by 6.49% to $25.8 million in 2024, then dropped by 8.62% to $23.5 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $23.5 million, $24.4 million, and $25.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.